



September 10, 2024  
Press Release

Bay Adelaide Centre - North Tower  
40 Temperance Street, Suite 2700  
Toronto, ON M5H 0B4  
[www.helixbiopharma.com](http://www.helixbiopharma.com)

## **Helix BioPharma Corp. Announces Frankfurt Market Trading**

(TORONTO, Ontario) - Helix BioPharma Corp. (TSX: "HBP") (OTC PINK: HBPCD) (FRANKFURT: HBPO) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has commenced trading on the Frankfurt Boerse <https://www.boerse-frankfurt.de/aktie/helix-biopharma-new> under the following:

Trading symbol: HBPO  
WKN: A40GN1  
ISIN: CA4229102088

Coupled with its primary TSX and US quotation, the Company believes that the quotation on the Frankfurt Boerse in Germany, will make the Company more attractive to international financing opportunities and will allow for the Company to access a broader base of shareholders and investors, allowing it to get to the goal of completing its cancer treatments. Much of the approximately \$200,000,000 CAD historically raised by the Company from the time of its initial public offering to the present, was secured via European based investors and shareholders of record. Helix strongly believes that once its story is promulgated through the Frankfurt Boerse, European news, medical journals and electronic channels, it can attract a strong base of new investors who believe in its therapies and ultimate business goals.

On behalf of the Board of Directors of the Company,

HELIX BIOPHARMA CORP.

Jacek Antas, CEO and Director

**For more information, please contact:**  
[corporate@helixbiopharma.com](mailto:corporate@helixbiopharma.com)

THE TORONTO STOCK EXCHANGE ("TSX") HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE TSX'S REGULATION SERVICES PROVIDER.



September 10, 2024  
Press Release

Bay Adelaide Centre - North Tower  
40 Temperance Street, Suite 2700  
Toronto, ON M5H 0B4  
[www.helixbiopharma.com](http://www.helixbiopharma.com)

### **About Helix BioPharma Corp.**

Helix is a clinical-stage biopharmaceutical company developing unique therapies in the field of immunoncology, based on its proprietary technological platform DOS47.

For more information, please visit <http://helixbiopharma.com>

### **Forward-Looking Statements and Risks and Uncertainties**

*This news release contains forward-looking statements and information (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s listing on the Frankfurt Boerse and benefits thereof, anticipated access to a broader base of shareholders and investors, future business, operations, research and development, including the Company’s activities relating to DOS47. Forward-looking statements can further be identified by the use of forward-looking terminology such as “will”, “plans”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results. Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements are intended to provide information about management’s current plans and expectations regarding future operations and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release. The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including the risk factors discussed in the Company’s continuous disclosure record filed under the Company’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required.*